CD86 and cancer: Cancer cells can express regulatory ligands such as PD-L1, CD80/CD86, or Galectin-9 to provide a negative regulatory signal to T lymphocytes expressing their respective receptors PD-1, CTLA-4, and TIM-3, resulting in T cell exhaustion [137,138,139].